Cargando…
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
IMPORTANCE: The SARS-CoV-2 Omicron subvariant, BA.2, may be less severe than previous variants; however, confounding factors make interpreting the intrinsic severity challenging. OBJECTIVE: To compare the adjusted risks of mortality, hospitalization, intensive care unit admission, and invasive venti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597387/ https://www.ncbi.nlm.nih.gov/pubmed/36282501 http://dx.doi.org/10.1001/jamanetworkopen.2022.38354 |
_version_ | 1784816080960618496 |
---|---|
author | Strasser, Zachary H. Greifer, Noah Hadavand, Aboozar Murphy, Shawn N. Estiri, Hossein |
author_facet | Strasser, Zachary H. Greifer, Noah Hadavand, Aboozar Murphy, Shawn N. Estiri, Hossein |
author_sort | Strasser, Zachary H. |
collection | PubMed |
description | IMPORTANCE: The SARS-CoV-2 Omicron subvariant, BA.2, may be less severe than previous variants; however, confounding factors make interpreting the intrinsic severity challenging. OBJECTIVE: To compare the adjusted risks of mortality, hospitalization, intensive care unit admission, and invasive ventilation between the BA.2 subvariant and the Omicron and Delta variants, after accounting for multiple confounders. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study that applied an entropy balancing approach. Patients in a multicenter inpatient and outpatient system in New England with COVID-19 between March 3, 2020, and June 20, 2022, were identified. EXPOSURES: Cases were assigned as being exposed to the Delta (B.1.617.2) variant, the Omicron (B.1.1.529) variant, or the Omicron BA.2 lineage subvariants. MAIN OUTCOMES AND MEASURES: The primary study outcome planned before analysis was risk of 30-day mortality. Secondary outcomes included the risks of hospitalization, invasive ventilation, and intensive care unit admissions. RESULTS: Of 102 315 confirmed COVID-19 cases (mean [SD] age, 44.2 [21.6] years; 63 482 women [62.0%]), 20 770 were labeled as Delta variants, 52 605 were labeled as the Omicron B.1.1.529 variant, and 28 940 were labeled as Omicron BA.2 subvariants. Patient cases were excluded if they occurred outside the prespecified temporal windows associated with the variants or had minimal longitudinal data in the Mass General Brigham system before COVID-19. Mortality rates were 0.7% for Delta (B.1.617.2), 0.4% for Omicron (B.1.1.529), and 0.3% for Omicron (BA.2). The adjusted odds ratio of mortality from the Delta variant compared with the Omicron BA.2 subvariants was 2.07 (95% CI, 1.04-4.10) and that of the original Omicron variant compared with the Omicron BA.2 subvariant was 2.20 (95% CI, 1.56-3.11). For all outcomes, the Omicron BA.2 subvariants were significantly less severe than that of the Omicron and Delta variants. CONCLUSIONS AND RELEVANCE: In this cohort study, after having accounted for a variety of confounding factors associated with SARS-CoV-2 outcomes, the Omicron BA.2 subvariant was found to be intrinsically less severe than both the Delta and Omicron variants. With respect to these variants, the severity profile of SARS-CoV-2 appears to be diminishing after taking into account various factors including therapeutics, vaccinations, and prior infections. |
format | Online Article Text |
id | pubmed-9597387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-95973872022-11-14 Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England Strasser, Zachary H. Greifer, Noah Hadavand, Aboozar Murphy, Shawn N. Estiri, Hossein JAMA Netw Open Original Investigation IMPORTANCE: The SARS-CoV-2 Omicron subvariant, BA.2, may be less severe than previous variants; however, confounding factors make interpreting the intrinsic severity challenging. OBJECTIVE: To compare the adjusted risks of mortality, hospitalization, intensive care unit admission, and invasive ventilation between the BA.2 subvariant and the Omicron and Delta variants, after accounting for multiple confounders. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study that applied an entropy balancing approach. Patients in a multicenter inpatient and outpatient system in New England with COVID-19 between March 3, 2020, and June 20, 2022, were identified. EXPOSURES: Cases were assigned as being exposed to the Delta (B.1.617.2) variant, the Omicron (B.1.1.529) variant, or the Omicron BA.2 lineage subvariants. MAIN OUTCOMES AND MEASURES: The primary study outcome planned before analysis was risk of 30-day mortality. Secondary outcomes included the risks of hospitalization, invasive ventilation, and intensive care unit admissions. RESULTS: Of 102 315 confirmed COVID-19 cases (mean [SD] age, 44.2 [21.6] years; 63 482 women [62.0%]), 20 770 were labeled as Delta variants, 52 605 were labeled as the Omicron B.1.1.529 variant, and 28 940 were labeled as Omicron BA.2 subvariants. Patient cases were excluded if they occurred outside the prespecified temporal windows associated with the variants or had minimal longitudinal data in the Mass General Brigham system before COVID-19. Mortality rates were 0.7% for Delta (B.1.617.2), 0.4% for Omicron (B.1.1.529), and 0.3% for Omicron (BA.2). The adjusted odds ratio of mortality from the Delta variant compared with the Omicron BA.2 subvariants was 2.07 (95% CI, 1.04-4.10) and that of the original Omicron variant compared with the Omicron BA.2 subvariant was 2.20 (95% CI, 1.56-3.11). For all outcomes, the Omicron BA.2 subvariants were significantly less severe than that of the Omicron and Delta variants. CONCLUSIONS AND RELEVANCE: In this cohort study, after having accounted for a variety of confounding factors associated with SARS-CoV-2 outcomes, the Omicron BA.2 subvariant was found to be intrinsically less severe than both the Delta and Omicron variants. With respect to these variants, the severity profile of SARS-CoV-2 appears to be diminishing after taking into account various factors including therapeutics, vaccinations, and prior infections. American Medical Association 2022-10-25 /pmc/articles/PMC9597387/ /pubmed/36282501 http://dx.doi.org/10.1001/jamanetworkopen.2022.38354 Text en Copyright 2022 Strasser ZH et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Strasser, Zachary H. Greifer, Noah Hadavand, Aboozar Murphy, Shawn N. Estiri, Hossein Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England |
title | Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England |
title_full | Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England |
title_fullStr | Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England |
title_full_unstemmed | Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England |
title_short | Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England |
title_sort | estimates of sars-cov-2 omicron ba.2 subvariant severity in new england |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597387/ https://www.ncbi.nlm.nih.gov/pubmed/36282501 http://dx.doi.org/10.1001/jamanetworkopen.2022.38354 |
work_keys_str_mv | AT strasserzacharyh estimatesofsarscov2omicronba2subvariantseverityinnewengland AT greifernoah estimatesofsarscov2omicronba2subvariantseverityinnewengland AT hadavandaboozar estimatesofsarscov2omicronba2subvariantseverityinnewengland AT murphyshawnn estimatesofsarscov2omicronba2subvariantseverityinnewengland AT estirihossein estimatesofsarscov2omicronba2subvariantseverityinnewengland |